Skip to main content Skip to search Skip to main navigation

EMA: Guiding Principles on LLMs, a Category of Generative AI

On 5 September 2024 the EMA and the Heads of Medicine Agencies HMA, published guiding principles that set how EU medicine regulators can use large language models (LLMs), a form of generative AI, focusing on text generation in regulatory science and for regulatory activities. The 10-page document provides high-level recommendations to facilitate LLMs' safe, responsible, and effective use, being of interest to anyone who uses or would like to use such AI models in the future.

"LLMs have enormous transformative potential," says EMA, “but also present challenges: variability in results, returning of irrelevant or inaccurate responses (so-called hallucinations), and potential data security risks." On the other hand, LLMs could be applied to query the extensive documentation regulators receive, to automate knowledge/data mining processes, or as virtual AI assistants in everyday administrative tasks.

Therefore, the document aims to build an understanding of the capabilities and limitations of these applications among staff at regulatory agencies across the EU to harness the potential of LLMs effectively and avoid pitfalls and risks. General ethical considerations, e.g. the rule of law, accountability, security, safety, transparency, non-discrimination, misinformation harms, and malicious uses or copyright issues are included.

Being part of the multiannual AI work plan to 2028 set out by EMA, the guiding principles are considered a living document that will be regularly updated. An EMA factsheet on LLMs can be found here.


Source:

EMA: Guiding principles on the use of LLMs in regulatory science and for medicines regulatory activities

EMA: Factsheet on the 4 principles for safe and responsible use of LLMs

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
EU: Analysis Supporting the Proposed Biotech Act

EU: Analysis Supporting the Proposed Biotech Act

The European Commission has published the analysis underpinning the proposed Biotech Act. The initiative aims to strengthen Europe’s biotechnology and biomanufacturing sectors and to accelerate the development, production and market uptake of biotechnology-based innovations.
Read more
EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.
Read more
What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
Previous
Next